Breast conservation therapy for early stage breast carcinoma with outstanding 10-year locoregional control rates: a case for aggressive therapy to the tumor bearing quadrant
- PMID: 8226147
- DOI: 10.1016/0360-3016(93)90378-9
Breast conservation therapy for early stage breast carcinoma with outstanding 10-year locoregional control rates: a case for aggressive therapy to the tumor bearing quadrant
Abstract
Purpose: Between 1982 and 1988 233 American Joint Committee on Cancer Stage I and II invasive breast carcinomas were prospectively treated in 225 women with conservative tumor excision, careful assessment of histopathological margins, and dose-adjusted irradiation to maximum doses of 70 Gy to the tumor bearing quadrant of the breast.
Methods and materials: The pathological stages at presentation were T1N0 and T1N1 in 57% and 13% and T2N0 and T2N1 in 19% and 10% of the patients, respectively. All patients were irradiated according to a policy that, beyond the 50 Gy to the whole breast and draining lymphatics, the tumor-bearing quadrant was boosted in adjustment to the histopathological margin. Normal tissue margins of < 2 mm were considered positive, margins 2-5 mm close, and margins > 5 mm negative and were boosted with 20, 15, and 10 Gy, respectively. Patients in whom the margin could not be assessed were re-excised or boosted to 20 Gy. Re-excisions with no residual carcinoma were not boosted. Most patients boosted to 20 Gy to the tumor-bearing quadrant received interstitial 192-Ir implantations.
Results: The actuarial local control rates in the treated breast were 97.5% at 10 years with three recurrences having occurred at a median of 4.5 years after completion of radiotherapy. An additional two patients failed regionally outside the irradiation portals. The overall and disease-free survival of the whole group is 87.5% and 77%, respectively.
Conclusion: The approach to breast conservation therapy followed in this study has resulted in outstanding local control rates and suggests that there may be a subset of patients that could be irradiated to the tumor bearing quadrant only.
Comment in
-
Conservative treatment of early breast cancer: what is important?Int J Radiat Oncol Biol Phys. 1994 Sep 30;30(2):503-4. doi: 10.1016/0360-3016(94)90039-6. Int J Radiat Oncol Biol Phys. 1994. PMID: 7928479 No abstract available.
Similar articles
-
The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation.Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):105-15. doi: 10.1016/s0360-3016(98)00181-3. Int J Radiat Oncol Biol Phys. 1998. PMID: 9747827
-
Factors determining outcome for breast-conserving irradiation with margin-directed dose escalation to the tumor bed.Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):851-8. doi: 10.1016/s0360-3016(97)00861-4. Int J Radiat Oncol Biol Phys. 1998. PMID: 9531370
-
Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial.Lancet Oncol. 2017 Feb;18(2):259-268. doi: 10.1016/S1470-2045(17)30011-6. Epub 2017 Jan 14. Lancet Oncol. 2017. PMID: 28094198 Clinical Trial.
-
Selection criteria for breast conservation in breast cancer.Eur J Surg. 2000 Nov;166(11):835-46. doi: 10.1080/110241500447209. Eur J Surg. 2000. PMID: 11097148 Review.
-
Breast conservation therapy in the management of invasive and in situ carcinoma.R I Med. 1995 Sep;78(9):246-9. R I Med. 1995. PMID: 7579719 Review. No abstract available.
Cited by
-
Cosmetic effect in patients with early breast cancer treated with breast conserving therapy (BCT) and with HDR brachytherapy (HDR-BT) "boost".J Contemp Brachytherapy. 2009 Jun;1(2):77-86. Epub 2009 Jul 17. J Contemp Brachytherapy. 2009. PMID: 27795716 Free PMC article.
-
The role of boost irradiation in the conservative treatment of stage I-II breast cancer.Pathol Oncol Res. 2001;7(4):241-50. doi: 10.1007/BF03032380. Pathol Oncol Res. 2001. PMID: 11882903 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical